Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Final analysis of a 52‐week phase 3 open‐label study

In this 52‐week, phase 3 open‐label study, efficacy and safety of adalimumab were evaluated in Japanese patients with active ulcers due to pyoderma gangrenosum (PG) during a 26‐week treatment period and another 26‐week extension period. Patients received adalimumab 160 mg at week 0, 80 mg at week 2,...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Kenshi, Yamanaka, Keiichi, Zhao, Yiwei, Iwano, Shunsuke, Takei, Keiko, Suzuki, Koji, Yamamoto, Toshiyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313851/
https://www.ncbi.nlm.nih.gov/pubmed/35243682
http://dx.doi.org/10.1111/1346-8138.16337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313851/
https://www.ncbi.nlm.nih.gov/pubmed/35243682
http://dx.doi.org/10.1111/1346-8138.16337

Ejemplares similares